Gerhard Kraus, Global Head of IT Infrastructure
Gerhard Kraus, Global Head of IT Infrastructure "Improving the health of humans and animals is our vision. What we do can make a huge impact"
Search
Living with pulmonary fibrosis and finding hope
From caregiver to co-founder of the European Pulmonary Fibrosis Federation, Liam Galvin shares about his experience, and the impact of ongoing research
Boehringer Ingelheim Venture Fund invests precision antimicrobials
Boehringer Ingelheim Venture Fund invests in the development of precision antimicrobials
Boehringer Ingelheim becomes member of IPC
Boehringer Ingelheim becomes member of IPC Boehringer Ingelheim is proud to join the International Poultry Council thus reaffirming its strong long-term commitment to shaping the future of poultry health. The International Poultry Council represents a uni
Boehringer Ingelheim Innovation Prize Video 2023
Boehringer Ingelheim's Innovation Prize provides valuable resources to help early-stage companies progress their science.
Jean-Michel Boers Appointed to PhRMA Board of Directors
Jean-Michel Boers Appointed to PhRMA Board of Directors
AMR_Action_Fund
Boehringer Ingelheim joins AMR Action Fund to support antibiotic R&D
FIBRONEER™ Phase III program initiated
FIBRONEER™ Phase III program initiated globally to evaluate BI 1015550, a novel investigational phosphodiesterase 4B (PDE4B) inhibitor
emperor-reduced-heart-failure-toplineresults
Positive, top-line results announced from the EMPEROR-Reduced Phase III trial in adults with chronic heart failure with reduced ejection fraction
ATM-Ranking-2021
Boehringer Ingelheim climbs two places. New early-stage research projects for disease areas relevant to low-to-middle income countries not reflected.
bix_facilitates_global_partnerships
BI X focuses on partnerships to speed up the development of digital healthcare solutions
Their dogs are their world
Corporate social responsibility in Brazil: Volunteer work and animal healthcare donations for homeless people and their pets.
vaxxitek® hvt + ibd + nd
Bursal Disease-Marek's disease-Newcastle disease vaccine, serotype 3, live Marek's disease vector; the vaccine includes a diluent
2021 ABCD Young Scientist Award feline health
Young veterinary researchers Julia Klaus and Dr Yasmin Parr receive award for their work into feline SARS-CoV-2 infections and feline leukaemia virus.
FOYA_Shanghai
Boehringer Ingelheim’s commercial manufacturing facility in Shanghai has been awarded as “Facility of the Year”
Boehringer Ingelheim announces collaboration with MabGenesis
Boehringer Ingelheim announces collaboration with MabGenesis to discover and develop novel monoclonal antibodies in canine
Innovation and drone delivery
Addressing healthcare disparities through collaborative innovation and drone delivery
Targeting Tumor Stroma
Boehringer Ingelheim’s research approach in stromal biology may lead to new medicines that will change the face of cancer and give new hope to patients
Agreement-to-acquire-NBE-Therapeutics
Boehringer Ingelheim to acquire NBE-Therapeutics to significantly enhance cancer pipeline portfolio with antibody-drug conjugates.
Imagine: The impact of volunteering activities on elderly well-being
How our employees contribute to elderly well-being with creative volunteering activities in Australia, South Korea, Southeast Asia, and New Zealand.
Overcoming heartworm disease for homeless pets
Heartworm-free pets soar to new lives. Together with our Greater Good Charity partners, our colleagues helped bring shelter dogs to forever homes.
GioTag Final Data
Final analysis of GioTag study data showed sequential afatinib followed by osimertinib is a feasible therapeutic strategy in EGFR M+ NSCLC patients
EMPRISE
Learn about the EMPRISE real-world evidence study and use of empagliflozin in routine clinical care
Expert insights: the top online lung cancer questions answered
As part of Big Little Things, we teamed up with top patient representatives from around the world to answer the most searched questions about lung cancer.
EMPRISE-Study
EMPRISE-Study